top of page
2016: Lyme establishment publish (again) that Lyme is an immunosuppression disease.
Gary Wormser, Allen Steere, CDC officer Paul Mead, and others admit Late Lyme and LYMErix diseases are immunosuppression outcomes, saying the “TLR2/1 agonism” (immunosuppression) is probably the “more important” driver of the disease outcome, here.
“This finding suggests that there is redundancy in the ability of the innate immune system to recognize B. burgdorferi and/or that these components can activate pathways that produce anti-inflammatory cytokine…the anti-inflammatory effects might be the more important function of TLR signaling.”
bottom of page